Clinical toxicity of interferons in cancer patients: a review.
about
Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic painImmune Responses Against Classical Swine Fever Virus: Between Ignorance and LunacyTreatment of Cancer Pain by Targeting CytokinesAnti-hepatitis C virus drugs and kidneyPractical management of classical myeloproliferative disorder patients: a clinician's guideInterferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels.Cardiomyopathy associated with high-dose interleukin-2 therapy.Cytokines in immune function and sleep regulation.Interferon-induced cutaneous necrosis.Hepatitis C virus associated glomerulopathies.Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism.Genetic aspects of inherent B-cell abnormalities associated with SLE and B-cell malignancy: lessons from New Zealand mouse models.Interferon-mediated fatigue.I'm so tired: biological and genetic mechanisms of cancer-related fatigueCytokine therapeutics: lessons from interferon alphaAcute renal failure during interferon treatmentInterferon type I receptor-deficient mice have altered disease symptoms in response to influenza virusEfficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsRetinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature.Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.Concise review: cell therapies: the route to widespread adoption.The kidney in oncology.Evolving therapeutic paradigms for multiple myeloma: back to the future.Interferon for treatment: the dust settles.The role of interferons in the treatment of malignant neoplasms.Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.Liver injury after aluminum potassium sulfate and tannic acid treatment of hemorrhoids.Coley's Lessons Remembered: Augmenting Mistletoe Therapy.Interferon Induced Focal Segmental Glomerulosclerosis.Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization.Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab.Interferon associated retinopathy.Multiple systemic expression of human interferon-beta in mice can be achieved upon repeated administration of optimized pcTG90-lipoplex.Constant and steady transgene expression of interferon-γ by optimization of plasmid construct for safe and effective interferon-γ gene therapy.Adverse Events in Cancer Immunotherapy.Design of Insulin-Loaded Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation.Investigation of the ototoxic effects of interferon alpha2A on the mouse cochlea.
P2860
Q24634125-98F55849-F24E-4A5D-AACE-A2EA934CC75CQ26776096-AF245160-9619-450B-A172-78CC964B65FCQ26779917-9BF7677E-BE94-4294-BFDB-FBD8AB1677F4Q28070279-4C717B27-6404-4DD7-8BB0-45B6D63EF7B0Q28200207-7403B2B2-86DC-4A71-AD24-36E08894FBCEQ33390973-4DFBAAD5-78E8-48C3-B807-81C930D4C2ADQ33559591-C169C7E0-39F7-413B-934B-AAC1A8C61D3AQ33716410-1EAE295F-0B6F-42FC-9885-3B152E08C0D2Q33780949-4D43A44A-E78C-4E04-ABF7-D3DB91FD6A73Q33801278-D4E751DF-027E-4F5D-96D2-2D9ACA39627FQ33866418-0A4D58EA-F157-4A56-A0AE-2A481E2CF888Q33979195-034316C5-575D-43EF-8BE2-BDEDDFE70A4AQ34051992-EF549D49-4F56-4C6D-A46F-6D7C34346816Q34400101-DDD3AA98-391B-4CBD-8141-64281E9E5B9CQ34543971-30B511C3-3E61-4605-A3B1-16860178B5F6Q35033232-E33A4E8A-1744-4960-9BA3-0E40D443DC6DQ35187655-DA4532EC-6D8B-4871-A526-3DA036DF7927Q35676400-51EAB8F2-CF2A-4E2A-93EF-3857C1F33C8BQ35763133-C92FCB66-FB86-4534-ADC6-36D61F51A856Q35863891-3C1FCC5E-E6CC-4E35-9CD2-AF7362B980B8Q36549261-13476FFE-FE42-4BBF-A56A-D2ED029C9FBFQ36587700-ECF421A8-4C56-4570-8928-A480600B44A6Q36861566-86C950A9-9B5A-4027-A986-F6D051C273E3Q36900332-C7F42C2E-D163-4232-B8CA-68BB477F4B7AQ38033590-ACB13538-B562-44B0-8736-FB8BA10407ACQ38190337-751B3B41-97A0-46D1-995F-951DCEB86C37Q38208932-D53B9493-C35B-4E44-A504-10770988915BQ38262786-E22EED29-0424-4DDB-9890-5A1A9D580D9CQ38645739-60EE23CB-076B-4B34-8DC5-27B9B79A394BQ38840254-7D030D85-FE61-4391-A500-19F3AAE26D11Q40450393-768A54FF-9A9B-41AD-B55F-A7FB1C04249CQ41865084-92DCEFC4-0AFF-4470-BEF6-1EFE0D23565DQ42116278-543F6FE5-781A-4DA6-AF11-2A1BCA7C7829Q42368351-00ACD4D8-6B14-40E8-BE38-64DCC3CAB3B8Q43094927-F164737A-B4E8-4238-B14A-7CF7BB0ED514Q45871435-ECF2ED8C-FED0-4B09-BA4A-3E2C849FDCBAQ45877387-9033AB78-A8BD-460D-8859-073F9867AC8EQ46884498-2C78FA33-97A8-4C05-A977-327C41709A8FQ48097918-707262C0-CD81-4100-A684-7EDC2009C933Q48966591-80752314-991D-4AE8-BC46-C4D9E147ADDE
P2860
Clinical toxicity of interferons in cancer patients: a review.
description
1986 nî lūn-bûn
@nan
1986 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Clinical toxicity of interferons in cancer patients: a review.
@ast
Clinical toxicity of interferons in cancer patients: a review.
@en
type
label
Clinical toxicity of interferons in cancer patients: a review.
@ast
Clinical toxicity of interferons in cancer patients: a review.
@en
prefLabel
Clinical toxicity of interferons in cancer patients: a review.
@ast
Clinical toxicity of interferons in cancer patients: a review.
@en
P2093
P356
P1476
Clinical toxicity of interferons in cancer patients: a review.
@en
P2093
P304
P356
10.1200/JCO.1986.4.2.234
P407
P577
1986-02-01T00:00:00Z